{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:06:02Z","timestamp":1768251962269,"version":"3.49.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,5]]},"DOI":"10.7759\/cureus.16201","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T03:55:25Z","timestamp":1625543725000},"source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Peripherally Acting \u03bc-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Martina","family":"Rekatsina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Paladini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asbj\u00f8rn M","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrah","family":"Ayob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Corli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Pergolizzi Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30008-6","article-title":"Pathophysiology, diagnosis, and management of opioid-induced constipation","volume":"3","author":"Farmer AD","year":"2018","unstructured":"Farmer AD, Holt CB, Downes TJ, Ruggeri E, Del Vecchio S, De Giorgio R. Pathophysiology, diagnosis, and management of opioid-induced constipation. Lancet Gastroenterol Hepatol. 2018, 3:203-212. 10.1016\/S2468-1253(18)30008-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00271-y","article-title":"Impact and consequences of opioid-induced constipation: a survey of patients [PREPRINT]","author":"Varrassi G","year":"2021","unstructured":"Varrassi G, Banerji V, Gianni W, Marinangeli F, Pinto C. Impact and consequences of opioid-induced constipation: a survey of patients [PREPRINT]. Pain Ther. 2021, 10.1007\/s40122-021-00271-y","journal-title":"Pain Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-013-0344-2","article-title":"Opioid-induced bowel dysfunction","volume":"15","author":"Ketwaroo GA","year":"2013","unstructured":"Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep. 2013, 15:344. 10.1007\/s11894-013-0344-2","journal-title":"Curr Gastroenterol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12718","article-title":"The impact of opioid-induced constipation among chronic pain patients with sufficient laxative use","volume":"69","author":"LoCasale RJ","year":"2015","unstructured":"LoCasale RJ, Datto CJ, Margolis MK, Tack J, Coyne KS. The impact of opioid-induced constipation among chronic pain patients with sufficient laxative use. Int J Clin Pract. 2015, 69:1448-56. 10.1111\/ijcp.12718","journal-title":"Int J Clin Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ajgsup.2014.4","article-title":"Pharmacology of opioids and their effects on gastrointestinal function","volume":"2","author":"Holzer P","year":"2014","unstructured":"Holzer P. Pharmacology of opioids and their effects on gastrointestinal function. Am J Gastroenterol Suppl. 2014, 2:9-16. 10.1038\/ajgsup.2014.4","journal-title":"Am J Gastroenterol Suppl"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-3150.2004.00553.x","article-title":"The opioid system in the gastrointestinal tract","volume":"16 Suppl 2","author":"Sternini C","year":"2004","unstructured":"Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004, 16 Suppl 2:3-16. 10.1111\/j.1743-3150.2004.00553.x","journal-title":"Neurogastroenterol Motil"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ajgsup.2014.5","article-title":"Molecular physiology of enteric opioid receptors","volume":"2","author":"Galligan JJ","year":"2014","unstructured":"Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014, 2:17-21. 10.1038\/ajgsup.2014.5","journal-title":"Am J Gastroenterol Suppl"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw255","article-title":"Opioid-induced constipation and bowel dysfunction: a clinical guideline","volume":"18","author":"M\u00fcller-Lissner S","year":"2017","unstructured":"M\u00fcller-Lissner S, Bassotti G, Coffin B, et al.. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017, 18:1837-63. 10.1093\/pm\/pnw255","journal-title":"Pain Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.02.008","article-title":"The impact of naloxegol on anal sphincter function - using a human experimental model of opioid-induced bowel dysfunction","volume":"117","author":"Gr\u00f8nlund D","year":"2018","unstructured":"Gr\u00f8nlund D, Poulsen JL, Krogh K, et al.. The impact of naloxegol on anal sphincter function - using a human experimental model of opioid-induced bowel dysfunction. Eur J Pharm Sci. 2018, 117:187-92. 10.1016\/j.ejps.2018.02.008","journal-title":"Eur J Pharm Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4784-7","article-title":"Prolonged-release oxycodone\/naloxone improves anal sphincter relaxation compared to oxycodone plus Macrogol 3350","volume":"62","author":"Poulsen JL","year":"2017","unstructured":"Poulsen JL, Brock C, Gr\u00f8nlund D, Liao D, Gregersen H, Krogh K, Drewes AM. Prolonged-release oxycodone\/naloxone improves anal sphincter relaxation compared to oxycodone plus Macrogol 3350. Dig Dis Sci. 2017, 62:3156-66. 10.1007\/s10620-017-4784-7","journal-title":"Dig Dis Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1049909106289068","article-title":"The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain","volume":"23","author":"Glare P","year":"2006","unstructured":"Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006, 23:229-35. 10.1177\/1049909106289068","journal-title":"Am J Hosp Palliat Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01458.x","article-title":"Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain","volume":"22","author":"Tuteja AK","year":"2010","unstructured":"Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010, 22:424-30, e96. 10.1111\/j.1365-2982.2009.01458.x","journal-title":"Neurogastroenterol Motil"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjpain.2015.12.005","article-title":"Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction - recommendations of the Nordic Working Group","volume":"11","author":"Drewes AM","year":"2016","unstructured":"Drewes AM, Munkholm P, Simr\u00e9n M, et al.. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction - recommendations of the Nordic Working Group. Scand J Pain. 2016, 11:111-22. 10.1016\/j.sjpain.2015.12.005","journal-title":"Scand J Pain"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002024","article-title":"Opioid-induced constipation in patients with cancer: a \"real-world,\" multicentre, observational study of diagnostic criteria and clinical features","volume":"162","author":"Davies A","year":"2021","unstructured":"Davies A, Leach C, Butler C, et al.. Opioid-induced constipation in patients with cancer: a \"real-world,\" multicentre, observational study of diagnostic criteria and clinical features. Pain. 2021, 162:309-18. 10.1097\/j.pain.0000000000002024","journal-title":"Pain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.851082","article-title":"Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study","volume":"16","author":"Abramowitz L","year":"2013","unstructured":"Abramowitz L, B\u00e9ziaud N, Labreze L, et al.. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013, 16:1423-33. 10.3111\/13696998.2013.851082","journal-title":"J Med Econ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65321","article-title":"Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain","volume":"21","author":"Devulder J","year":"2005","unstructured":"Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005, 21:1555-68. 10.1185\/030079905X65321","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2009.0014","article-title":"Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey","volume":"5","author":"Bell T","year":"2009","unstructured":"Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009, 5:137-44. 10.5055\/jom.2009.0014","journal-title":"J Opioid Manag"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2019.32.2.69","article-title":"Opioid-induced constipation: a narrative review of therapeutic options in clinical management","volume":"32","author":"Lang-Illievich K","year":"2019","unstructured":"Lang-Illievich K, Bornemann-Cimenti H. Opioid-induced constipation: a narrative review of therapeutic options in clinical management. Korean J Pain. 2019, 32:69-78. 10.3344\/kjp.2019.32.2.69","journal-title":"Korean J Pain"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.02.009","article-title":"The burden of opioid adverse events and the influence on cancer patients'","volume":"57","author":"Corli O","year":"2019","unstructured":"Corli O, Santucci C, Corsi N, Radrezza S, Galli F, Bosetti C. The burden of opioid adverse events and the influence on cancer patients'. J Pain Symptom Manage. 2019, 57:899-908.e6. 10.1016\/j.jpainsymman.2019.02.009","journal-title":"J Pain Symptom Manage"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/15360280903098440","article-title":"Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy","volume":"23","author":"Candrilli SD","year":"2009","unstructured":"Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009, 23:231-41. 10.1080\/15360280903098440","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1)","volume":"10","author":"Bell TJ","year":"2009","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009, 10:35-42. 10.1111\/j.1526-4637.2008.00495.x","journal-title":"Pain Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.657301","article-title":"The Bowel Function Index: a new validated scale for assessing opioid-induced constipation","volume":"28","author":"Ducrott\u00e9 P","year":"2012","unstructured":"Ducrott\u00e9 P, Causs\u00e9 C. The Bowel Function Index: a new validated scale for assessing opioid-induced constipation. Curr Med Res Opin. 2012, 28:457-66. 10.1185\/03007995.2012.657301","journal-title":"Curr Med Res Opin"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2020.1708718","article-title":"An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation","volume":"14","author":"Aziz I","year":"2020","unstructured":"Aziz I, Whitehead WE, Palsson OS, T\u00f6rnblom H, Simr\u00e9n M. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Rev Gastroenterol Hepatol. 2020, 14:39-46. 10.1080\/17474124.2020.1708718","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel Disorders","volume":"150","author":"Mearin F","year":"2016","unstructured":"Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016, 150:1393-407. 10.1053\/j.gastro.2016.02.031","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0885-3924(01)00369-4","article-title":"Low-dose oral naloxone reverses opioid-induced constipation and analgesia","volume":"23","author":"Liu M","year":"2002","unstructured":"Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002, 23:48-53. 10.1016\/s0885-3924(01)00369-4","journal-title":"J Pain Symptom Manage"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618818305","article-title":"Pathophysiology and management of opioid-induced constipation: European expert consensus statement","volume":"7","author":"Farmer AD","year":"2019","unstructured":"Farmer AD, Drewes AM, Chiarioni G, De Giorgio R, O'Brien T, Morlion B, Tack J. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J. 2019, 7:7-20. 10.1177\/2050640618818305","journal-title":"United European Gastroenterol J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.01.021","article-title":"Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis","volume":"16","author":"Nee J","year":"2018","unstructured":"Nee J, Zakari M, Sugarman MA, et al.. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018, 16:1569-1584.e2. 10.1016\/j.cgh.2018.01.021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref29","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells G","year":"2016","unstructured":"Wells G, Shea B, O'Connell D, et al.. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2016."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12899","article-title":"Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation","volume":"40","author":"Webster L","year":"2014","unstructured":"Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014, 40:771-9. 10.1111\/apt.12899","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/2050640615604543","article-title":"Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response","volume":"3","author":"Tack J","year":"2015","unstructured":"Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United European Gastroenterol J. 2015, 3:471-80. 10.1177\/2050640615604543","journal-title":"United European Gastroenterol J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.04.024","article-title":"A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation","volume":"154","author":"Webster L","year":"2013","unstructured":"Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013, 154:1542-50. 10.1016\/j.pain.2013.04.024","journal-title":"Pain"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.012","article-title":"Translating clinical findings into the patient's perspective: post-hoc pooled analysis of bowel movement changes as a predictor of improvement in patients' opioid-induced constipation symptoms and outcomes","volume":"39","author":"Coyne KS","year":"2017","unstructured":"Coyne KS, Poon JL, Thompson C, Hu Y, Datto CJ, Sostek M. Translating clinical findings into the patient's perspective: post-hoc pooled analysis of bowel movement changes as a predictor of improvement in patients' opioid-induced constipation symptoms and outcomes. Clin Ther. 2017, 39:75-88. 10.1016\/j.clinthera.2016.11.012","journal-title":"Clin Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.06.012","article-title":"A randomized, placebo-controlled phase 3 trial (Study SB-767905\/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain","volume":"12","author":"Jansen JP","year":"2011","unstructured":"Jansen JP, Lorch D, Langan J, et al.. A randomized, placebo-controlled phase 3 trial (Study SB-767905\/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011, 12:185-93. 10.1016\/j.jpain.2010.06.012","journal-title":"J Pain"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S160625","article-title":"Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone","volume":"11","author":"Webster LR","year":"2018","unstructured":"Webster LR, Israel RJ. Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone. J Pain Res. 2018, 11:2509-16. 10.2147\/JPR.S160625","journal-title":"J Pain Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2007.12.005","article-title":"Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study","volume":"35","author":"Portenoy RK","year":"2008","unstructured":"Portenoy RK, Thomas J, Moehl Boatwright ML, et al.. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008, 35:458-68. 10.1016\/j.jpainsymman.2007.12.005","journal-title":"J Pain Symptom Manage"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707377","article-title":"Methylnaltrexone for opioid-induced constipation in advanced illness","volume":"358","author":"Thomas J","year":"2008","unstructured":"Thomas J, Karver S, Cooney GA, et al.. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008, 358:2332-43. 10.1056\/NEJMoa0707377","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2014.0362","article-title":"Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension","volume":"18","author":"Bull J","year":"2015","unstructured":"Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med. 2015, 18:593-600. 10.1089\/jpm.2014.0362","journal-title":"J Palliat Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.003","article-title":"Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms","volume":"14","author":"Iyer SS","year":"2011","unstructured":"Iyer SS, Randazzo BP, Tzanis EL, Schulman SL, Zhang H, Wang W, Manley AL. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health. 2011, 14:177-83. 10.1016\/j.jval.2010.11.003","journal-title":"Value Health"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.11.008","article-title":"Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","volume":"12","author":"Michna E","year":"2011","unstructured":"Michna E, Blonsky ER, Schulman S, et al.. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011, 12:554-62. 10.1016\/j.jpain.2010.11.008","journal-title":"J Pain"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12535","article-title":"Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain","volume":"17","author":"Rauck R","year":"2017","unstructured":"Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract. 2017, 17:820-8. 10.1111\/papr.12535","journal-title":"Pain Pract"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnx148","article-title":"Long-term safety and efficacy of subcutaneous methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain: a phase 3, open-label trial","volume":"18","author":"Webster LR","year":"2017","unstructured":"Webster LR, Michna E, Khan A, Israel RJ, Harper JR. Long-term safety and efficacy of subcutaneous methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain: a phase 3, open-label trial. Pain Med. 2017, 18:1496-504. 10.1093\/pm\/pnx148","journal-title":"Pain Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S170086","article-title":"Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain","volume":"12","author":"Rauck RL","year":"2019","unstructured":"Rauck RL, Slatkin NE, Stambler N, Israel RJ. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. J Pain Res. 2019, 12:139-50. 10.2147\/JPR.S170086","journal-title":"J Pain Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.3.367","article-title":"Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial","volume":"283","author":"Yuan CS","year":"2000","unstructured":"Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MF. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000, 283:367-72. 10.1001\/jama.283.3.367","journal-title":"JAMA"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.02.234","article-title":"Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness","volume":"38","author":"Chamberlain BH","year":"2009","unstructured":"Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009, 38:683-90. 10.1016\/j.jpainsymman.2009.02.234","journal-title":"J Pain Symptom Manage"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2011.573531","article-title":"Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study","volume":"25","author":"Lipman AG","year":"2011","unstructured":"Lipman AG, Karver S, Cooney GA, Stambler N, Israel RJ. Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study. J Pain Palliat Care Pharmacother. 2011, 25:136-45. 10.3109\/15360288.2011.573531","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12218","article-title":"Efficacy and tolerability of subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: a responder analysis of 2 randomized, placebo-controlled trials","volume":"15","author":"Nalamachu SR","year":"2015","unstructured":"Nalamachu SR, Pergolizzi J, Taylor R Jr, et al.. Efficacy and tolerability of subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: a responder analysis of 2 randomized, placebo-controlled trials. Pain Pract. 2015, 15:564-71. 10.1111\/papr.12218","journal-title":"Pain Pract"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.1.118","article-title":"Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial","volume":"300","author":"Yuan CS","year":"2002","unstructured":"Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002, 300:118-23. 10.1124\/jpet.300.1.118","journal-title":"J Pharmacol Exp Ther"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00753-2","article-title":"Safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy: a subgroup analysis of patients\u2009\u2265\u200965 years of age","volume":"37","author":"Wild J","year":"2020","unstructured":"Wild J, Webster L, Yamada T, Hale M. Safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy: a subgroup analysis of patients\u2009\u2265\u200965 years of age. Drugs Aging. 2020, 37:271-9. 10.1007\/s40266-020-00753-2","journal-title":"Drugs Aging"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8453","article-title":"Phase IIB, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer","volume":"35","author":"Katakami N","year":"2017","unstructured":"Katakami N, Oda K, Tauchi K, et al.. Phase IIB, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. J Clin Oncol. 2017, 35:1921-8. 10.1200\/JCO.2016.70.8453","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami N","year":"2017","unstructured":"Katakami N, Harada T, Murata T, et al.. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017, 35:3859-66. 10.1200\/JCO.2017.73.0853","journal-title":"J Clin Oncol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE- 2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale M","year":"2017","unstructured":"Hale M, Wild J, Reddy J, et al.. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE- 2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017, 2:555-64. 10.1016\/S2468-1253(17)30105-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw325","article-title":"A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain","volume":"18","author":"Webster LR","year":"2017","unstructured":"Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2017, 18:2350-60. 10.1093\/pm\/pnw325","journal-title":"Pain Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001174","article-title":"Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study","volume":"159","author":"Webster LR","year":"2018","unstructured":"Webster LR, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T, Arjona Ferreira JC. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018, 159:987-94. 10.1097\/j.pain.0000000000001174","journal-title":"Pain"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S175900","article-title":"Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies","volume":"12","author":"Saito Y","year":"2019","unstructured":"Saito Y, Yokota T, Arai M, Tada Y, Sumitani M. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies. J Pain Res. 2019, 12:127-38. 10.2147\/JPR.S175900","journal-title":"J Pain Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.07.001","article-title":"Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument","volume":"105","author":"Tompkins DA","year":"2009","unstructured":"Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009, 105:154-9. 10.1016\/j.drugalcdep.2009.07.001","journal-title":"Drug Alcohol Depend"},{"key":"ref58","unstructured":"2019 first generic drug approvals. (2019). Accessed. May 28, 2021: https:\/\/www.fda.gov\/drugs\/first-generic-drug-approvals\/2019-first-generic-drug-approvals."},{"key":"ref59","unstructured":"FDA indications for the use of PAMORAs. (2017). Accessed. July 4, 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021775lbl.pdf."},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03150.x","article-title":"Meta-analysis: alvimopan vs. placebo in the treatment of post-operative ileus","volume":"25","author":"Tan EK","year":"2007","unstructured":"Tan EK, Cornish J, Darzi AW, Tekkis PP. Meta-analysis: alvimopan vs. placebo in the treatment of post-operative ileus. Aliment Pharmacol Ther. 2007, 25:47-57. 10.1111\/j.1365-2036.2006.03150.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0b013e318249fc78","article-title":"A meta-analysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recovery program after abdominal surgery","volume":"55","author":"Vaughan-Shaw PG","year":"2012","unstructured":"Vaughan-Shaw PG, Fecher IC, Harris S, Knight JS. A meta-analysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recovery program after abdominal surgery. Dis Colon Rectum. 2012, 55:611-20. 10.1097\/DCR.0b013e318249fc78","journal-title":"Dis Colon Rectum"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14546","article-title":"Alvimopan as part of the Enhanced Recovery After Surgery protocol following radical cystectomy is associated with decreased hospital stay","volume":"28","author":"Hanna P","year":"2021","unstructured":"Hanna P, Regmi S, Kalapara A, et al.. Alvimopan as part of the Enhanced Recovery After Surgery protocol following radical cystectomy is associated with decreased hospital stay. Int J Urol. 2021, 28:696-701. 10.1111\/iju.14546","journal-title":"Int J Urol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyz005","article-title":"The impact of alvimopan on return of bowel function after major spine surgery - a prospective, randomized, double-blind study","volume":"85","author":"Dunn LK","year":"2019","unstructured":"Dunn LK, Thiele RH, Lin MC, et al.. The impact of alvimopan on return of bowel function after major spine surgery - a prospective, randomized, double-blind study. Neurosurgery. 2019, 85:E233-9. 10.1093\/neuros\/nyz005","journal-title":"Neurosurgery"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-020-02621-9","article-title":"Efficacy and safety of alvimopan use in benign urinary tract reconstruction","volume":"53","author":"Hensley P","year":"2021","unstructured":"Hensley P, Higgins M, Rasper A, et al.. Efficacy and safety of alvimopan use in benign urinary tract reconstruction. Int Urol Nephrol. 2021, 53:77-82. 10.1007\/s11255-020-02621-9","journal-title":"Int Urol Nephrol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1149017","article-title":"Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review","volume":"128","author":"Mehta N","year":"2016","unstructured":"Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review. Postgrad Med. 2016, 128:282-9. 10.1080\/00325481.2016.1149017","journal-title":"Postgrad Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000001854","article-title":"Improved bowel function with oral methylnaltrexone following posterior spinal fusion for adolescent idiopathic scoliosis","author":"Lin AJ","year":"2021","unstructured":"Lin AJ, Costandi AJ, Kim E, et al.. Improved bowel function with oral methylnaltrexone following posterior spinal fusion for adolescent idiopathic scoliosis. J Pediatr Orthop. 2021, 10.1097\/BPO.0000000000001854","journal-title":"J Pediatr Orthop"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000000840","article-title":"Methylnaltrexone-associated bowel perforation in postoperative opioid-induced constipation and Ogilvie syndrome","volume":"12","author":"Blackney KA","year":"2019","unstructured":"Blackney KA, Kamdar NV, Liu CA, Edwards DA. Methylnaltrexone-associated bowel perforation in postoperative opioid-induced constipation and Ogilvie syndrome. A A Pract. 2019, 12:44-6. 10.1213\/XAA.0000000000000840","journal-title":"A A Pract"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.01.011","article-title":"Methylnaltrexone and gastrointestinal perforation","volume":"40","author":"Mackey AC","year":"2010","unstructured":"Mackey AC, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage. 2010, 40:e1-3. 10.1016\/j.jpainsymman.2010.01.011","journal-title":"J Pain Symptom Manage"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0357-2","article-title":"Naloxegol: a review of its use in patients with opioid-induced constipation","volume":"75","author":"Garnock-Jones KP","year":"2015","unstructured":"Garnock-Jones KP. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015, 75:419-25. 10.1007\/s40265-015-0357-2","journal-title":"Drugs"},{"key":"ref70","unstructured":"Moventig. (2014). Accessed. May 28, 2021: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/moventig."},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.281.any","article-title":"Efficacy of naldemedine for the treatment of opioid-induced constipation: a meta-analysis","volume":"28","author":"Esmadi M","year":"2019","unstructured":"Esmadi M, Ahmad D, Hewlett A. Efficacy of naldemedine for the treatment of opioid-induced constipation: a meta-analysis. J Gastrointestin Liver Dis. 2019, 28:41-6. 10.15403\/jgld.2014.1121.281.any","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1570845","article-title":"A meta-analysis of naldemedine for the treatment of opioid-induced constipation","volume":"12","author":"Song X","year":"2019","unstructured":"Song X, Wang D, Qu X, Dong N, Teng S. A meta-analysis of naldemedine for the treatment of opioid-induced constipation. Expert Rev Clin Pharmacol. 2019, 12:121-8. 10.1080\/17512433.2019.1570845","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000527","article-title":"Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies","volume":"4","author":"Osaka I","year":"2019","unstructured":"Osaka I, Ishiki H, Yokota T, Tada Y, Sato H, Okamoto M, Satomi E. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies. ESMO Open. 2019, 4:e000527. 10.1136\/esmoopen-2019-000527","journal-title":"ESMO Open"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.690","article-title":"The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of naldemedine","volume":"9","author":"Fukumura K","year":"2020","unstructured":"Fukumura K, Yamada T, Yokota T, Kawasaki A. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of naldemedine. Clin Pharmacol Drug Dev. 2020, 9:162-74. 10.1002\/cpdd.690","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S237833","article-title":"A renal impairment subgroup analysis of the safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy","volume":"13","author":"Webster LR","year":"2020","unstructured":"Webster LR, Hale ME, Yamada T, Wild JE. A renal impairment subgroup analysis of the safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy. J Pain Res. 2020, 13:605-12. 10.2147\/JPR.S237833","journal-title":"J Pain Res"},{"key":"ref76","unstructured":"Drug trials snapshots. SYMPROIC. (2017). Accessed: May 28, 2021: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-symproic.."},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00195-z","article-title":"What to do and what not to do in the management of opioid-induced constipation: a choosing wisely report","volume":"9","author":"Alvaro D","year":"2020","unstructured":"Alvaro D, Caraceni AT, Coluzzi F, et al.. What to do and what not to do in the management of opioid-induced constipation: a choosing wisely report. Pain Ther. 2020, 9:657-67. 10.1007\/s40122-020-00195-z","journal-title":"Pain Ther"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw317","article-title":"Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer","volume":"27","author":"Janku F","year":"2016","unstructured":"Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016, 27:2032-8. 10.1093\/annonc\/mdw317","journal-title":"Ann Oncol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.02.015","article-title":"Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials","volume":"42","author":"Slatkin NE","year":"2011","unstructured":"Slatkin NE, Lynn R, Su C, Wang W, Israel RJ. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011, 42:754-60. 10.1016\/j.jpainsymman.2011.02.015","journal-title":"J Pain Symptom Manage"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00237-0","article-title":"Efficacy and safety of methylnaltrexone for the treatment of opioid-induced constipation: a meta-analysis of randomized controlled trials","volume":"10","author":"Zhang YY","year":"2021","unstructured":"Zhang YY, Zhou R, Gu WJ. Efficacy and safety of methylnaltrexone for the treatment of opioid-induced constipation: a meta-analysis of randomized controlled trials. Pain Ther. 2021, 10:165-79. 10.1007\/s40122-021-00237-0","journal-title":"Pain Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62501-efficacy-and-safety-of-peripherally-acting--opioid-receptor-antagonist-pamoras-for-the-management-of-patients-with-opioid-induced-constipation-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:18Z","timestamp":1707506778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62501-efficacy-and-safety-of-peripherally-acting--opioid-receptor-antagonist-pamoras-for-the-management-of-patients-with-opioid-induced-constipation-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":80,"URL":"https:\/\/doi.org\/10.7759\/cureus.16201","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,5]]}}}